Open semenko opened 1 year ago
Congrats on the paper!
These are lovely tools, but the research use only restriction / noncommercial limit for .pat/.beta will likely limit adoption.
Would y'all consider relicensing just that component to something less restrictive?
Congrats on the paper!
These are lovely tools, but the research use only restriction / noncommercial limit for .pat/.beta will likely limit adoption.
Would y'all consider relicensing just that component to something less restrictive?